Revelation Biosciences, Inc. (NASDAQ:REVB) Sees Significant Growth in Short Interest

Revelation Biosciences, Inc. (NASDAQ:REVB) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 428,600 shares, a growth of 937.8% from the October 31st total of 41,300 shares. Based on an average trading volume of 541,700 shares, the days-to-cover ratio is currently 0.8 days. Currently, 10.0% of the shares of the stock are short sold.

Revelation Biosciences Stock Performance

NASDAQ:REVB traded up $0.01 during mid-day trading on Thursday, hitting $0.76. 130,818 shares of the company’s stock traded hands, compared to its average volume of 853,882. The firm’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $1.33. Revelation Biosciences has a 1 year low of $0.70 and a 1 year high of $25.26. The company has a market cap of $3.24 million, a PE ratio of -0.05 and a beta of 0.15.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.